Open AccessTall-cell variant of papillary thyroid carcinoma: literature review and case reports
Author(s) -
Е. В. Бородавина,
П. А. Исаев,
Ф. С. Севрюков,
А. В. Сидорин,
В. В. Полькин,
А. А. Ильин,
Н. В. Северская,
Т. А. Агабабян,
С. А. Иванов,
А. Д. Каприн
Publication year - 2020
Publication title -
opuholi golovy i šei
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.14
H-Index - 1
eISSN - 2411-4634
pISSN - 2222-1468
DOI - 10.17650/2222-1468-2020-10-3-48-54
Subject(s) - lenvatinib , medicine , thyroid carcinoma , malignancy , papillary carcinoma , oncology , papillary thyroid cancer , carcinoma , pathology , thyroid , cancer research , thyroid cancer
The tall-cell variant of papillary thyroid carcinoma is a rare malignancy characterized by an aggressive course, low relapse-free survival, early metastasis, and frequent development of radioiodine refractoriness. We report two cases of tall-cell papillary thyroid carcinoma in patients who had disease progression after combination treatment and started to receive lenvatinib. We observed partial and complete regression of metastases in response to lenvatinib. Our findings are consistent with the results of other studies assessing treatment efficacy for disseminated tall-cell papillary thyroid carcinoma.